News & Updates

In the first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), adding the anti-PD-1 monoclonal antibody toripalimab to a standard chemotherapy regimen can significantly cut the risk of progression or death without an increase in adverse events, according to the prespecified analysis of the phase III JUPITER-06 trial.

Treatment with a nonhallucinogenic phytocannabinoid, cannabidivarin, is well tolerated in children with Rett syndrome (RTT), according to data from a phase 1 trial. Moreover, it improves seizure control in those whose disease is caused by methyl-CpG-binding protein 2 (MECP2) pathogenic variants.

Patients with major depressive disorder (MDD) generally achieve satisfactory treatment response with antipsychotic treatment, used either as monotherapy or adjunctively, a meta-analysis has shown. However, this benefit comes with an increased risk of adverse events.

Cases of the rare monkeypox viral disease have been detected in at least 12 countries and experts are cautiously concerned about yet another health disaster.

Around 75 percent of patients on clozapine develop treatment-induced gastrointestinal hypomotility (CIGH), which contributes to substantial risks of serious morbidity and mortality, a study reports.